Stereotactic Radiosurgery

Series
Radiotherapy
Status
Published
Date
Number of report
025

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for Stereotactic Radiosurgery (SRS) in European countries.      

The analysis covers the application of SRS in primary and secondary malignant brain tumours.

The analysis is provided for the session and out-patient treatment, including both preparation and delivery of SRS. The only reimbursement within public / statutory health insurance systems is considered.

The report includes essential information about reimbursement, including:

  • Brief country-specific overview of reimbursement system
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions on indications or scenarios for the use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • Finland
  • France
  • Germany
  • Italy
  • The Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of equipment for stereotactic radiosurgery include:

  • Accuray (CyberKnife)  
  • Brainlab (Novalis)
  • Elekta (Versa HD, Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, Leksell Gamma Knife 4C, Leksell Gamma Knife 4)
  • Varian Medical Systems (Edge, TrueBeam, Clinac iX)

Table of content 

1.    Introduction and summary
2.    Executive summary table

2.1.    Stereotactic radiosurgery
2.2.    Fractionated stereotactic radiotherapy
3.    Contents
4.    Abbreviations
5.    Methodology
6.    What’s new

7.    Reimbursement analysis in Austria
7.1.    Overview of the reimbursement system
7.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
7.2.1.    Procedure coding
7.2.2.    Diagnosis coding
7.2.3.    Payment mechanism and reimbursement tariffs in outpatient settings
7.2.4.    Payment mechanism and reimbursement tariffs in hospital admission
7.2.5.    Health technology assessments by LBI-HTA
8.    Reimbursement analysis in Belgium
8.1.    Overview of the reimbursement system
8.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
8.2.1.    Procedure coding
8.2.2.    Payment mechanism and reimbursement tariffs
8.2.3.    Conditions of reimbursement for radiotherapy in Belgium
8.2.4.    Policy considerations by the INAMI/RIZIV
8.2.5.    Health technology assessments by KCE
8.2.6.    Breast cancer in women: diagnosis, treatment and follow-up
9.    Reimbursement analysis in Denmark
9.1.    Overview of the reimbursement system
9.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
9.2.1.    Procedure coding 
9.2.2.    Diagnosis coding
9.2.3.    Payment mechanism and reimbursement tariffs
9.2.4.    Policy considerations
10.    Reimbursement analysis in England
10.1.    Overview of the reimbursement system
10.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
10.2.1.    Procedure coding 
10.2.2.    Diagnosis coding
10.2.3.    Payment mechanism and reimbursement tariffs
10.2.4.    Policy considerations 
10.2.4.1.    Specifics of commissioning of the procedure
10.2.4.2.    Health technology assessments by NICE
11.    Reimbursement analysis in Finland
11.1.    Overview of the reimbursement system
11.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
11.2.1.    Procedure coding 
11.2.2.    Diagnosis coding
11.2.3.    Payment mechanism and reimbursement tariffs
11.2.4.    Policy considerations
12.    Reimbursement analysis in France
12.1.    Overview of the reimbursement system
12.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
12.2.1.    Procedure coding 
12.2.2.    Diagnosis coding
12.2.3.    Payment mechanism and reimbursement tariffs for session treatment
12.2.4.    Payment mechanism and reimbursement tariffs in hospital admission
12.2.5.    Policy considerations by HAS
13.    Reimbursement analysis in Germany
13.1.    Overview of the reimbursement system
13.2.    Reimbursement analysis for stereotactic radiosurgery and radiotherapy
13.2.1.    Reimbursement analysis for stereotactic radiosurgery and radiotherapy in outpatient setting 
13.2.2.    Procedure coding
13.2.3.    Payment mechanism and reimbursement tariffs
13.2.4.    Reimbursement analysis for stereotactic radiosurgery in hospital admission
13.2.5.    Procedure coding 
13.2.6.    Diagnosis coding
13.2.7.    Payment mechanism and reimbursement tariffs
13.2.8.    Selective contracts
13.2.9.    Policy considerations by G-BA
14.    Reimbursement analysis in Italy
14.1.    Overview of the reimbursement system
14.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
14.2.1.    Procedure coding at national level
14.2.2.    Procedure coding at regional level (Emilia-Romagna, Lombardy, Veneto regions)
14.2.3.    Diagnosis coding
14.2.4.    Payment mechanism and reimbursement tariffs at national level
14.2.5.    Payment mechanism and reimbursement tariffs at regional level
14.2.6.    Policy considerations
15.    Reimbursement analysis in the Netherlands
15.1.    Overview of the reimbursement system
15.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
15.2.1.    Procedure coding 
15.2.2.    Diagnosis coding
15.2.3.    Payment mechanism and reimbursement tariffs
15.2.4.    Policy considerations by Dutch Healthcare Institute (ZIN)
16.    Reimbursement analysis in Norway
16.1.    Overview of the reimbursement system
16.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
16.2.1.    Procedure coding 
16.2.2.    Diagnosis coding
16.2.3.    Payment mechanism and reimbursement tariffs
16.2.4.    Policy considerations 
17.    Reimbursement analysis in Sweden
17.1.    Overview of the reimbursement system
17.2.    Reimbursement for stereotactic radiosurgery and radiotherapy
17.2.1.    Procedure coding 
17.2.2.    Diagnosis coding
17.2.3.    Payment mechanism and reimbursement tariffs
17.2.4.    Policy considerations 
18.    Reimbursement analysis in Switzerland
18.1.    Overview of the reimbursement system
18.2.    Reimbursement analysis for stereotactic radiosurgery and radiotherapy 
18.2.1.    Reimbursement analysis for stereotactic radiosurgery and radiotherapy in outpatient setting
18.2.2.    Procedure coding 
18.2.3.    Payment mechanism and reimbursement tariffs
18.2.4.    Reimbursement analysis for stereotactic radiosurgery during hospital admission
18.2.5.    Procedure coding 
18.2.6.    Diagnosis coding
18.2.7.    Payment mechanism and reimbursement tariffs
18.2.8.    Policy considerations
19.    Summary of procedure codes
20.    Summary of reimbursement codes and tariffs
21.    Disclaimer

30

Sep 2021

At the beginning of September 2021, the Government of the Russian Federation released the preliminary version of the Program of State Guarantees for the period of 2022-2024. Major changes concerned the High-End Medical Care (HEMC) list I, where two new procedures in the cardiovascular and neurovascular field were added. The HEMC list II was expanded with the procedures in the field of radiotherapy, neurology, and neurosurgery, surgical procedures. The final version is expected at the beginning of 2022.

Read more

01

Sep 2021

On August 05, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering April 27, 2021 - July 27, 2021). No new MedTech-related Clinical Commissioning Policies were added to the work program. Nine new policies were published; however, only two concerned MedTech (ECMO and brachytherapy). The status of ongoing policies was updated as well.

Read more

26

Jul 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.

Read more

05

Jul 2021

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more
(we accept only company emails)